BCMA in Multiple Myeloma—A Promising Key to Therapy

Despite the discoveries of numerous agents including next generation proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, multiple myeloma (MM) remains an incurable disease. The field of myeloma treatment in refractory or relapsed patients after standard therapy entered a new er...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleber, Martina, Ntanasis-Stathopoulos, Ioannis, Terpos, Evangelos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472544/
https://www.ncbi.nlm.nih.gov/pubmed/34575199
http://dx.doi.org/10.3390/jcm10184088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472544/
https://www.ncbi.nlm.nih.gov/pubmed/34575199
http://dx.doi.org/10.3390/jcm10184088

Ejemplares similares